Eli Lilly posted what analysts called a 'blowout quarter,' fueled by robust international sales of its diabetes drug Mounjaro. The company responded by raising its full-year guidance for both profit and revenue, signaling confidence in its growth trajectory.
While Mounjaro's performance overseas drove the upside, attention is now shifting to the launch of Lilly's next-generation obesity drug, Foundayo. The company has positioned Foundayo as a key growth driver in the increasingly competitive weight-loss market.
Lilly did not disclose specific sales figures for Mounjaro or Foundayo in the context of this report. The raised guidance reflects broad operational strength rather than a single product beat.
The market opportunity in obesity remains enormous, with Lilly and rivals like Novo Nordisk vying for dominance. Foundayo's commercial success will be critical to sustaining Lilly's momentum beyond Mounjaro's patent life.
Some analysts caution that Foundayo's launch faces headwinds from pricing pressures and supply constraints, which could temper the initial revenue contribution.